A European Bioanalysis Forum recommendation for requiring a context-of-use statement for successful development and validation of biomarker assays
Open Access
- 5 August 2024
- journal article
- research article
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (16) , 835-842
Abstract
The European Bioanalysis Forum, alongside key industry stakeholders, has been driving the discussions around the implementation of context-of use for biomarker assays to ensure that these assays are validated appropriately depending on their purpose. Insights into understanding why the implementation of context-of-use in assay strategies has also shown that the key stakeholder, or requester for the biomarker data, is responsible for providing the context-of-use statement for all biomarker assay requests. Experts from across the industry haves repeatedly sought a cross-industry recommended format in which the context-of-use statement could be provided. In this manuscript, the European Bioanalysis Forum suggests a format for this.Keywords
This publication has 9 references indexed in Scilit:
- Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis ForumBioanalysis, 2024
- A Biomarker Assay Validation Approach Tailored to The Context of Use and Bioanalytical PlatformBioanalysis, 2023
- Biomarker Context-Of-Use: How Organizational Design Can Impact the Implementation of the Appropriate Biomarker Assay StrategyBioanalysis, 2022
- Applying Contextofuse to Quantitative Polymerase Chain Reaction Method Validation and Analysis: A Recommendation From the European Bioanalysis ForumBioanalysis, 2021
- Recommendations and discussion points on immunogenicity, biomarkers, automation/technology and protein–MS from the 2021 European Bioanalysis Forum Focus WorkshopsBioanalysis, 2021
- Update to the European Bioanalysis Forum Recommendation on Biomarkers Assays; Bringing Context of Use Into PracticeBioanalysis, 2020
- What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?Journal of Patient-Reported Outcomes, 2020
- Evolving Our Thinking on Biomarker Assay Validation: Are we Ready for the Next Leap?Bioanalysis, 2019
- European Bioanalysis Forum Recommendation on Method Establishment And Bioanalysis of Biomarkers in Support of Drug DevelopmentBioanalysis, 2012